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Abstract
Background: Coronaviruses (CoVs) can be classified into alphacoronavirus (group 1), betacoronavirus (group 2), and
gammacoronavirus (group 3) based on diversity of the protein sequences. Their 3C-like protease (3CL
pro), which catalyzes
the proteolytic processing of the polyproteins for viral replication, is a potential target for anti-coronaviral infection.
Methodology/Principal Findings: Here, we profiled the substrate specificities of 3CL
pro from human CoV NL63 (group 1),
human CoV OC43 (group 2a), severe acute respiratory syndrome coronavirus (SARS-CoV) (group 2b) and infectious
bronchitis virus (IBV) (group 3), by measuring their activity against a substrate library of 1968 of variants with single
substitutions at P5 to P3’ positions. The results were correlated with structural properties like side chain volume,
hydrophobicity, and secondary structure propensities of substituting residues. All 3CL
pro prefer Gln at P1 position, Leu at P2
position, basic residues at P3 position, small hydrophobic residues at P4 position, and small residues at P1’ and P2’ positions.
Despite 3CL
pro from different groups of CoVs share many similarities in substrate specificities, differences in substrate
specificities were observed at P4 positions, with IBV 3CL
pro prefers P4-Pro and SARS-CoV 3CL
pro prefers P4-Val. By combining
the most favorable residues at P3 to P5 positions, we identified super-active substrate sequences ‘VARLQQSGF’ that can be
cleaved efficiently by all 3CL
pro with relative activity of 1.7 to 3.2, and ‘VPRLQQSGF’ that can be cleaved specifically by IBV
3CL
pro with relative activity of 4.3.
Conclusions/Significance: The comprehensive substrate specificities of 3CL
pro from each of the group 1, 2a, 2b, and 3 CoVs
have been profiled in this study, which may provide insights into a rational design of broad-spectrum peptidomimetic
inhibitors targeting the proteases.
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Introduction
A number of coronaviruses (CoVs) have been identified as
causative agents of respiratory tract and gastroenteritis diseases in
mammals and birds [1,2,3,4,5,6,7,8,9,10,11]. Sequence analysis
suggests that these coronaviral strains can be classified into three
main groups – alphacoronavirus (group 1), betacoronavirus (group
2), and gamacoronavirus (group 3) [12]. The sequence of severe
acute respiratorysyndrome coronavirus (SARS-CoV), discovered in
2003, was found to be diverse from any existing groups of CoVs.
The group 2 CoVs are then further divided into 2a and 2b sub-
groups, with the original group 2 CoVs assigned to group 2a and
SARS-CoV to group 2b [13,14]. Most of coronaviral strains are
group 1 and 2a members. They include the four human
coronaviruses (HCoVs) strains, NL63, 229E, OC43 and HKU1,
that associate with up to 5% of total respiratory tract disease cases
[15,16]. The most infamous strain in group 3 is infectiousbronchitis
virus (IBV), which can cause lethal infections in birds [17,18].
3C-like protease (3CL
pro), which is also named main protease, is
responsible for the processing of the viral polyproteins into at least
15 non-structural proteins, most of which are constituents of the
viral replication and transcription complex. The cleavage process
can be acted in cis and in trans [19]. This enzyme is a good drug
target for anti-coronaviral infection, as inhibiting the autocleavage
process can inhibit viral replication and reduce virus-induced
cytopathic effects on host cells [20,21,22,23]. A detailed knowledge
of substrate specificity of 3CL
pro is helpful in the rational design of
inhibitors. Substrate specificity of SARS-CoV 3CL
pro was
extensively investigated after the outbreak of SARS in 2003. Fan
et al. measured the protease activity against 34 single-substituted
variants at P5 to P1’ positions, while Goetz et al. profiled the
specificity at P4 to P1 positions by using a fully degenerated library
of tetrapeptide mixtures [24,25]. Chuck et al. profiled the substrate
preference of SARS-CoV 3CL
pro by measuring the activity of
3CL
pro against substrate variants with single substitutions at P5 to
P3’ positions [26].
On the other hand, reports describing the substrate specificities
of 3CL
pro in group 1, 2a, and 3 are scarce. Only the activity of
3CL
pro from HCoV-229E (group 1), transmissible gastroenteritis
coronavirus (group 1) and mouse hepatitis virus (group 2a) against
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27228three to four of their own autocleavage sequences have been
measured by Hegyi et al. [27]. Comprehensive study on substrate
specificities of group 1, 2a and 3 3CL
pro is lacking. Here, we
profiled the substrate specificities of selected 3CL
pro from group 1,
2a, 2b and 3 CoVs. Activities of 3CL
pro from HCoV-NL63 (group
1), HCoV-OC43 (group 2a), SARS-CoV (group 2b) and IBV
(group 3) against a substrate library of 1968 variants were
measured by fluorescence resonance energy transfer (FRET) assay




Profiling substrate specificities of 3CL
pro from group 1,
2a, 2b, and 3 CoVs
We have previously created a 1968 substrate library by
performing saturation mutagenesis at P5 to P3’ positions on the
wild type (WT) sequence (SAVLQQSGF), which corresponds to
the autocleavage sequence at the N-terminus of SARS-CoV
3CL
pro [26]. The values of kobs/[3CL
pro] of the proteases against
this WT sequence were 443611, 124613, 18065 and
174619 mM
-1 min
-1 for HCoV-NL63 (group 1), HCoV-OC43
(group 2a), SARS-CoV (group 2b), and IBV (group 3),
respectively. That all proteases can cleave the WT sequence
efficiently justifies that we can use our substrate library to profile
the substrate specificities of 3CL
pro from other groups of CoVs.
Based on the FRET assay we developed, we measured the
activities of 3CL
pro from HCoV-NL63, HCoV-OC43, SARS-
CoV and IBV against the 1968 substrate variants (Figure 1, Table
S1) [26]. To identify the structural basis of substrate preferences
for different CoVs, the protease activities were correlated with side
chain volume [28], hydrophobicity [29], and a-helix and b-sheet
propensities [30] as described [26]. The correlations were
quantified in terms of correlation coefficients and p-values
(Figure 2, Table S2).
Differences in substrate specificities among 3CL
pro
We then tested if the relative activities of 3CL
pro from any CoV
strains were significantly different from the other by analysis of
variance. Substitutions that resulted in significantly higher relative
activities (p,0.001) were indicated as filled symbol in Figure 1.
IBV 3CL
pro (Figure 1, triangles) was the most efficient in cleaving
A4P and A4F with relative activities of 1.0960.24 and 0.5860.14,
respectively, while SARS 3CL
pro (Figure 1, diamonds) preferred
A4V with relative activity of 1.3960.19. HCoV-OC43 3CL
pro
(Figure 1, squares) appeared to be the most versatile in accepting
substitutions at P1 and P2 positions, and could cleave Q1H, Q1M,
L2M and L2C, significantly better than 3CL
pro from other strains.
No significant differences were observed for other substitutions,
suggesting that 3CL
pro from different CoVs shares many
similarities in substrate preferences.
Substrate preferences that are common to all 3CL
pro
The most preferred P1 residue is Gln (Figure 1), which forms
hydrogen-bonds with the side-chain of an invariant His residue
and the backbone carbonyl group of an invariant Phe residue (His-
163 and Phe-140 in SARS-CoV 3CL
pro) in the P1 binding pocket.
Interestingly, our results showed that 3CL
pro from all groups of
CoVs can cleave His at P1 position reasonably well. The relative
activities for 3CL
pro from HCoV-NL63, HCoV-OC43, SARS-
CoV, and IBV were 0.2660.08, 0.4760.08, 0.1960.03 and
0.2560.12, respectively (Table S1). Consistent with this observa-
tion, His is found natively at P1 positions in the polyproteins from
group 1 and 2a CoVs (Table S3). Taken together, the ability to
cleave His at P1 position is a conserved property for all 3CL
pro.
Moreover, we showed that all 3CL
pro can cleave Q1M, albeit at
Figure 1. Substrate specificity of 3CL
pro at P5 to P3’ positions. Relative protease activity of 3CL
pro from HCoV-NL63 (circles, group 1), HCoV-
OC43 (squares, group 2a), SARS-CoV (diamond, group 2b) and IBV (triples, group 3) against 1968 of substrate variants were measured by FRET assay.
Relative activities that are significantly (p-value,0.001) higher than the rest are represented as filled symbols.
doi:10.1371/journal.pone.0027228.g001
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undetected activity.
The protease activities correlate positively with the hydropho-
bicity of substituting residues at P2 position (Figure 2). In fact,
among the P2 variants, only L2M, L2C, L2F, L2I and L2V were
cleavable, suggesting that P2 position favors hydrophobic residues.
However, substitution with b-branched residues, Val or Ile, led to
.10-folds decreases in the activity (Figure 1, Table S1).
Considering that Leu, Val and Ile share similar hydrophobicity
and side chain volume, the large differences in activities suggest
that b-branched residues are not preferred in all 3CL
pro, probably
due to steric clashes with the P2 binding pocket. Taken together,
P2 position prefers hydrophobic residues without b-branch, and
the most preferred residue is Leu.
At P3 position, the protease activities on Arg/Lys-substituting
variants were 5 to 14 fold higher than that on Asp/Glu-
substituting variants (Figure 1, Table S1). This observation
suggests that P3 position prefers positively charged residues over
negatively charged one. In the active site of 3CL
pro, there is no
substrate-binding pocket for P3 residue. Molecular modeling
showed that there is an invariant Glu residue (Glu-166 in SARS-
CoV 3CL
pro) in the active site of 3CL
pro that may form favorable
charge-charge interactions with a positively charged residue at the
P3 position, which may explain why Arg/Lys are favored over
Asp/Glu at this position (Figure S1). Moreover, no cleavage was
observed for substrate containing Pro-substitution at P3 position.
The protease activities correlate negatively with side chain
volume, and positively with the hydrophobicity of substituting
residues at P4 position (Figure 2). The correlations with
hydrophobicity were more evident (with correlation coefficients
.0.89) when only small residues (Ala, Asn, Asp, Cys, Gly, Ser, and
Thr) with side chain volumes ,70 A ˚ 3 (Figure 3) were included in
the analysis. This result suggests that as long as the side chain can
fit into the P4 binding pocket, the protease activity is directly
proportional to the hydrophobicity of the substituting residues. On
the other hand, charged residues like Lys, Arg, His, Asp and Glu
were not cleavable, presumably due to the unfavorable burial of
charges in the hydrophobic P4 pocket.
In general, the activities of 3CL
pro correlate positively with the
hydrophobicity and b-sheet propensity of substituting residues at
P5 position (Figure 2). The correlations are significant (p,0.05) for
group 2a, 2b, and 3 CoVs, but are weaker for group 1 CoV. Like
the P3 position, there is no substrate-binding pocket for P5 residue.
In the crystal structure of SARS-CoV 3CL
pro in complex with a
peptide substrate, the P5 residue adopts an extended b-strand
conformation to avoid clashing of P5-P6 residues with the protease
[31]. Residues with high b-sheet propensity may stabilize the
extended conformation at P5 and improve enzyme-substrate
interaction. As shown in Figure 1, a number of substitutions at P5
position resulted in a substrate better than the WT sequence (i.e.
with relative activity .1). Consistent with the suggestion that P5
position favors residues with high hydrophobicity and b-sheet
Figure 2. Correlation between 3CL
pro activities and structural properties of substituting residues. The relative protease activities of
3CL
pro from HCoV-NL63 (shaded, group 1), HCoV-OC43 (white, group 2a), SARS-CoV (black, group 2b) and IBV (grey, group 3), were correlated with
structural properties of substituting residue properties, including side chain volume [28], hydrophobicity [29] and a-helix and b-sheet propensities
[30]. Correlation coefficients of +/20.56 and +/20.44 correspond to p-values of 0.01 and 0.05 respectively.
doi:10.1371/journal.pone.0027228.g002
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higher than WT activities for all 3CL
pro. On the other hand,
negatively charged residues (Asp/Glu) were not favored at P5
position, with significantly lower activities (0.16 to 0.50).
At P1’ position, the protease activities correlate negatively with
side chain volume of substituting residues (Figure 2). In fact, the
relative activities for substrates with the smallest residues (Gly, Ala,
Ser, and Cys) at P1’ position were in the range of 0.64 to 1.40,
which were consistently higher than those for other larger residues
(Figure 1). At P2’ position, all variants, except G2’P, could be
cleaved with relative activities of 0.17 to 1.04 (Figure 1). The
protease activities also correlate negatively with the side chain
volume (Figure 2), but the difference in the protease activities was
relatively small (Figure 1). At P3’ position, no obvious substrate
preference was observed.
The effect of combining multiple favorable substitutions
Our profiling analysis showed that all CoV 3CL
pro prefer P5-
Val and P3-Arg (Figure 1). To test if we can combine two
favorable substitutions to create a more active substrate, we have
created a doubly-substituted substrate variant ‘VARLQQSGF’.
The protease activities of HCoV-NL63, HCoV-OC43, SARS-
CoV and IBV against the doubly-substituted sequence were
1.7060.07, 1.8760.17, 1.7060.12 and 3.2460.37, respectively
(Table 1). The results suggest that the increase in activity is
additive, and the sequence ‘VARLQQSGF’ can represent a good
broad-spectrum substrate for all 3CL
pro.
On the other hand, our profiling analysis suggests that 3CL
pro
fromSARS-CoVandIBVhave differentsubstratepreferencesatP4
position – SARS-CoV prefers P4-Val (relative activity=1.0960.24)
while IBV prefers P4-Pro (relative activity=1.3960.10) (Figure 1,
Table S1). To see if we can exploit this distinct substrate preference
at P4 position to create a substrate more specific for IBV 3CL
pro,w e
have created the triply-substituted variant ‘VPRLQQSGF’. The
protease activity of IBV3CL
pro against this sequence wasboosted to
4.3360.98, while that of the other strains were significantly
reduced, demonstrating that this substrate sequence can represent
a specific substrate-sequence for IBV 3CL
pro (Table 1). Similarly,
the protease activity of SARS-CoV 3CL
pro against the triply-
substituted sequence ‘VVRLQQSGF’ was boosted to 2.5060.51,
while that of the other strains were reduced (Table 1). Taken
together, these results suggest that one can combine the substrate
preference profiled in this study to create a better substrate
sequences.
Discussion
This study provides the first comprehensive profiling of
substrate specificities of 3CL
pro from group 1, 2a, and 3 CoVs.
We showed that the substrate specificities of these 3CL
pro share
many similarities to those of 3CL
pro from SARS-CoV (group 2b)
reported previously by us [26]. Table 2 summarizes the substrate
Figure 3. All 3CL
pro prefer small hydrophobic residues at P4 position. All 3CL
pro activities are highly correlated to hydrophobicity of residues
with side chain volumes of ,70 A ˚3 (filled symbols). The correlation coefficients and the corresponding p-values are indicated.
doi:10.1371/journal.pone.0027228.g003
Table 1. 3CL
pro activities against doubly- and triply-
substituted substrate variants. WT substrate was substituted
at P3 to P5 positions to generate doubly- and triply-
substituted variants. The relative activities of 3CL
pro on these
substrate variants are reported.
Variant
sequence HCoV-NL63 HCoV-OC43 SARS-CoV IBV
VAVLQQSGF 1.2360.40 1.5560.30 1.8060.31 1.5860.27
SARLQQSGF 1.1460.24 1.3660.17 0.9760.12 1.7260.22
VARLQQSGF 1.7060.07 1.8760.17 1.7060.17 3.2460.37
SPVLQQSGF 0.0660.01 0.2960.07 0.6160.10 1.0960.24
VPRLQQSGF 0.1560.04 0.9160.12 0.9960.12 4.3360.98
SVVLQQSGF 0.7660.10 0.5960.07 1.3960.19 0.5960.09
VVVLQQSGF 1.2360.06 0.6060.05 1.9760.19 0.8660.05
VVRLQQSGF 1.6360.07 0.5560.04 2.5060.51 2.1960.13
doi:10.1371/journal.pone.0027228.t001




P5 No strong preference
P4 Small hydrophobic residues
P3 Positively charged residues




P3’ No strong preference
doi:10.1371/journal.pone.0027228.t002
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pro. Although the substrate
specificities for 3CL
pro from different groups of CoVs share a
number of similarities, unique substrate preferences were identi-
fied in this study. In particular, we showed that only IBV 3CL
pro,
but not other proteases, prefers P4-Pro (Figure 3).
To understand the structural basis of this unique substrate
preference, we compared the structures of IBV 3CL
pro with other
coronaviral 3CL
pro. We noticed that strand-11 of IBV 3CL
pro is
positioned further away from the P4 and P5 substrate-binding site
compared to other 3CL
pro (Figure 4) [31,32,33]. This results in a
wider substrate-binding pocket in IBV 3CL
pro. We further docked
the substrate variant A4P into the substrate-binding pocket of IBV
3CL
pro. Due to the cyclic structure of Pro residue, the backbone Ø
dihedral angle of the P4 residue is restrained to ca. 260u, which
causes the substrate peptide to bend towards the strand-11 of
3CL
pro. Such conformation of substrate is much better accom-
modated by IBV 3CL
pro, which has a wider substrate-binding
pocket near the P4 and P5 positions. This observation justifies why
only IBV 3CL
pro cleaves P4-Pro efficiently.
Similarities in substrate specificity suggest that it is feasible to
create a broad-spectrum inhibitor that targets all 3CL
pro. A broad-
spectrum inhibitor is desirable for a first line defense against
coronaviral infection because CoVs are capable of generating
novel strains with high virulence through high frequency of
mutations and recombination [34,35,36,37].. Based on the
autocleavage sequence of SARS-CoV 3CL
pro (i.e. AVLQQ),
Rao and co-workers designed broad-spectrum peptidomimetic
inhibitors that can inhibit 3CL
pro from different groups of CoVs
[20]. Their results are consistent with our observation that the
autocleavage sequence of SARS-CoV 3CL
pro can be well cleaved
by all 3CL
pro. The substrate preferences profiled in this study will
provide a rational basis to improve the broad-spectrum 3CL
pro
inhibitors. For example, by combining favorable substitutions at
P3 to P5 positions, we identified a substrate sequence
‘VARLQQSGF’ that can be cleaved with high relative activities
by 3CL
pro from all groups of CoVs (Table 1). This substrate
sequence may serve as a good starting point of the design of broad-
spectrum peptidomimetic inhibitors for 3CL
pro.
Although it is generally accepted that substrate specificity
provides insights into the design of peptidomimetic protease
inhibitors, there are exceptions to the dogma that good
peptidomimetic inhibitors should be derived from good substrate
sequences. For example, Hilgenfeld and co-workers showed that
the P2 position of peptide aldehyde inhibitors can accommodate
aspartate or serine, which are poor substrates for SARS-CoV
3CL
pro [38].
In the FRET assay developed by us, all 3CL
pro can efficiently
cleave the WT sequence of ‘SAVLQQSGF’ with activity of 120–
440 mM
21 min
21, and the activity can be further improved by 1.7
to 3.2 fold using the substrate sequence of ‘VARLQQSGF’.
Because the substrate sequences can be cleaved by all 3CL
pro with
high efficiency, one could use the FRET assay to screen for broad-
spectrum inhibitors targeting 3CL
pro from all groups of CoVs.
Materials and Methods
Cloning, Expression and Purification of 3CL
pro and the
Substrate Library
Cloning, expression and purification of SARS-CoV 3CL
pro
were described previously [26]. Codon-optimized DNA sequences
encoding HCoV-NL63 (GenBank AY567487) and HCoV-OC43
(GenBank AAX85666), and IBV (GenBank M95169) 3CL
pro were
purchased from Mr. Gene (http://mrgene.com). The coding
sequences of 3CL
pro from HCoV-NL63, HCoV-OC43 and IBV
were sub-cloned and expressed in E. coli strain BL21 (DE3) pLysS
as fusion proteins with N-terminal tags of poly-histidine-small
ubiquitin-related modifier (His6-SUMO) or poly-histidine-maltose
binding protein (His6-MBP). Protein expression was induced by
addition of 0.1 mM of isopropyl b-D-1-thiogalactopyranoside.
After overnight incubation at 25uC, cells were harvested by
centrifugation and resuspended in buffer A (20 mM Tris, pH 7.8,
150 mM NaCl and 1 mM tris(2-carboxyethyl)phosphine) with
30 mM imidazole and disrupted by sonication. Soluble fraction
was subject to immobilized metal ion affinity chromatography for
purification as described for SARS-CoV 3CL
pro [26]. The His6-
SUMO or His6-MBP tags were removed by protease digestion
using sentrin-specific protease 1 or factor Xa, respectively,
followed by immobilized metal ion affinity chromatography.
Native 3CL
pro were finally purified by G75 size exclusion column
and stored in buffer A. Elution profiles of size exclusion
chromatography indicated that all 3CL
pro purified were dimeric.
The construction, expression and purification of the substrate
library were described previously [26]. In brief, the WT substrate
sequence ‘TSAVLQQSGFRKM’ was inserted between the cyan
fluorescent protein and the yellow fluorescent protein to create the
substrate protein. Saturation mutagenesis was performed at each
of the P5 to P3’ positions to generate a substrate library of 1968
variants.
FRET assay for 3CL
pro activity measurement
The protease activity of 3CL
pro was measured by the FRET
assay we developed previously [26]. Purified 3CL
pro at 0.2 to
2 mM were mixed with 35 mM of the substrate protein in buffer A.
Cleavage of the substrate protein leads to a decrease in
fluorescence at 530 nm when the reaction mixture was excited
at 430 nm. The fluorescence intensity, monitored by EnVision
2101 Multilabel Plate Reader, was fitted to single exponential
Figure 4. IBV 3CL
pro has a wider substrate-binding pocket to
accommodate substrate containing P4-Pro. The structure of IBV
3CL
pro (PDB: 2Q6D, yellow cartoon and white surface) is superimposed
with 3CL
pro from HCoV-229E (PDB: 1P9S, light blue), HCoV-HKU1 (PDB:
3D23, light green), and SARS-CoV (PDB: 2Q6G, pink) [31,32,33]. The
structure of WT substrate (magenta) is derived from crystal structure of
SARS-CoV 3CL
pro in complex with the autocleavage sequence
(TSAVLQQSGFRKM) (PDB: 2Q6G) [31]. The structure of the A4P
substrate variant (cyan) was modeled based on the crystal structure
of IBV 3CL
pro in complex with its own autocleavage sequence (PDB:
2Q6D) [31]. Note that strand-11 of IBV 3CL
pro is positioned further away
from P4 to P5 positions, resulting in a wider substrate-binding pocket.
doi:10.1371/journal.pone.0027228.g004
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activity against variant substrates was normalized against the WT
activity to yield the relative activity. The assay was repeated in
triplicate.
Correlation analysis
Structural properties of substituting residues, including side
chain volume [28], hydrophobicity [29], and a-helix and b-sheet
propensities [30], were correlated with relative activity to
determine correlation coefficients (r) and p-values.
Supporting Information
Figure S1 Molecular modeling showing P3-Arg may
interact with Glu-166 of 3CL
pro. The model was based on
the crystal structure of 3CLpro (grey) in complex with a peptide
substrate ‘TSAVLQQSGFRK’ (yellow). P3-Val was replaced by
P3-Arg using the program PyMOL. As shown, the invariant Glu-
166 is in close proximity to P3-Arg, and may form favorable
charge-charge interaction to P3-Arg.
(TIF)
Table S1 Relative activities of HCoV-NL63, HCoV-OC43,
SARS-CoV and IBV 3CL
pro. ND stands for non-detectable
cleavage. The average and the standard deviation of three
measurements are shown.
(DOC)
Table S2 Correlation between activity of 3CL
pro and structural
properties of substituting residues. The correlation coefficients and
p-values (bracketed) are reported.
(DOC)
Table S3 Autocleavage sequences of 3CL
pro. PEDV, TGEV,
MHV, PHEV stand for porcine epidemic diarrhoea coronavirus,
transmissible gastroenteritis coronavirus, mouse hepatitis corona-
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